LRRK2 and Parkinson disease: These differences in kinase activity might explain the lifetime risk of PD in LRRK2 mutation carriers, with higher penetrance observed for LRRK2R1441C carriers [1,10], although with a later age of onset when compared with LRRK2G2019S carriers [1], illustrating that more complex mechanisms may be in action.